The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
The Concept of Prodromal Parkinson’s Disease
Open accessAbstract
Parkinson's disease (PD) is currently clinically defined by a set of cardinal motor features centred on the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, and imaging research suggests initiation of PD-specific pathology prior to appearance of these classical motor signs. This latent phase of neurodegeneration in PD is of particular relevance in relation to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease. A key challenge in PD research, therefore, is to identify and validate markers for the preclinical and prodromal stages of the illness. Currently, several nonmotor symptoms have been associated with an increased risk to develop PD in otherwise healthy individuals and ongoing research is aimed at validating a variety of candidate PD biomarkers based on imaging, genetic, proteomic, or metabolomic signatures, supplemented by work on tissue markers accessible to minimally invasive biopsies. In fact, the recently defined MDS research criteria for prodromal PD have included combinations of risk and prodromal markers allowing to define target populations of future disease modification trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
The Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationBarone, P., Antonini, A., Colosimo, C., Marconi, R., Morgante, L., Avarello, T. P., Bottacchi, E., Cannas, A., Ceravolo, G., Ceravolo, R., et al. (2009) · Movement Disorders · doi:10.1002/mds.22643 · Cited by 1,445
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,309
Self-citationColonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Chronic Behavioral Disorders of Human REM Sleep: A New Category of Parasomnia
Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986) · Sleep · doi:10.1093/sleep/9.2.293 · Cited by 1,150
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972
Frequency of Bowel Movements and the Future Risk of Parkinson’s Disease
Abbott, R. D., Petrovitch, H., White, L. R., Masaki, K. H., Tanner, C. M., Curb, J. D., Grandinetti, A., Blanchette, P. L., Popper, J. S., & Ross, G. W. (2001) · Neurology · doi:10.1212/wnl.57.3.456 · Cited by 839
Schenck, C. H., Boeve, B. F., & Mahowald, M. W. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2012.10.009 · Cited by 814
Non‐motor symptoms in Parkinson’s disease
Poewe, W. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02056.x · Cited by 782
Self-citationMeta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder
Postuma, R. B., Gagnon, J. F., Vendette, M., Fantini, M. L., Massicotte-Marquez, J., & Montplaisir, J. (2009) · Neurology · doi:10.1212/01.wnl.0000340980.19702.6e · Cited by 767
Association of olfactory dysfunction with risk for future Parkinson's disease
Ross, G. W., Petrovitch, H., Abbott, R. D., Tanner, C. M., Popper, J., Masaki, K., Launer, L., & White, L. R. (2008) · Annals of Neurology · doi:10.1002/ana.21291 · Cited by 742
Idiopathic hyposmia as a preclinical sign of Parkinson's disease
Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 740
Olfactory dysfunction in Parkinson disease
Doty, R. L. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.80 · Cited by 737
Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J. L., Valldeoriola, F., Serradell, M., Sanchez-Valle, R., Vilaseca, I., Lomeña, F., Vilas, D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70056-5 · Cited by 723
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., & Rüb, U. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1301-4 · Cited by 708
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People
Bennett, D. A., Beckett, L. A., Murray, A. M., Shannon, K. M., Goetz, C. G., Pilgrim, D. M., & Evans, D. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601113340202 · Cited by 659
Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B.-M. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 529
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study)
Pont‐Sunyer, C., Hotter, A., Gaig, C., Seppi, K., Compta, Y., Katzenschlager, R., Mas, N., Hofeneder, D., Brücke, T., Bayés, A., et al. (2015) · Movement Disorders · doi:10.1002/mds.26077 · Cited by 511
Self-citationMorrish, P. K., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 510
Berg, D., Postuma, R. B., Bloem, B., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Hardy, J., Lang, A. E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25844 · Cited by 506
Self-citationAlpha-synuclein in colonic submucosa in early untreated Parkinson’s disease
Shannon, K. M., Keshavarzian, A., Mutlu, E., Dodiya, H. B., Daian, D., Jaglin, J. A., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.23838 · Cited by 469
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study
Shiba, M., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<669::aid-mds1011>3.0.co;2-5 · Cited by 465
Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases
Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S., & Kordower, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25020 · Cited by 464
Excessive daytime sleepiness and subsequent development of Parkinson disease
Abbott, R. D., Ross, G. W., White, L. R., Tanner, C. M., Masaki, K. H., Nelson, J. S., Curb, J. D., & Petrovitch, H. (2005) · Neurology · doi:10.1212/01.wnl.0000183056.89590.0d · Cited by 440
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
Vaillancourt, D. E., Spraker, M. B., Prodoehl, J., Abraham, I., Corcos, D. M., Zhou, X. J., Comella, C. L., & Little, D. M. (2009) · Neurology · doi:10.1212/01.wnl.0000340982.01727.6e · Cited by 438
Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials
Postuma, R. B., Gagnon, J.-F., Bertrand, J.-A., Génier Marchand, D., & Montplaisir, J. Y. (2015) · Neurology · doi:10.1212/wnl.0000000000001364 · Cited by 436
Medical records documentation of constipation preceding Parkinson disease: A case-control study
Savica, R., Carlin, J. M., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Bharucha, A. E., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34af5 · Cited by 430
Lebouvier, T., Neunlist, M., Bruley des Varannes, S., Coron, E., Drouard, A., N'Guyen, J.-M., Chaumette, T., Tasselli, M., Paillusson, S., Flamand, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012728 · Cited by 427
The spectrum of nonmotor symptoms in early Parkinson disease
Khoo, T. K., Yarnall, A. J., Duncan, G. W., Coleman, S., O’Brien, J. T., Brooks, D. J., Barker, R. A., & Burn, D. J. (2013) · Neurology · doi:10.1212/wnl.0b013e31827deb74 · Cited by 427
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Kim, H. M., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418
Prevalence of smell loss in Parkinson's disease – A multicenter study
Haehner, A., Boesveldt, S., Berendse, H. W., Mackay-Sim, A., Fleischmann, J., Silburn, P. A., Johnston, A. N., Mellick, G. D., Herting, B., Reichmann, H., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.12.005 · Cited by 403
Berg, D., Roggendorf, W., Schröder, U., Klein, R., Tatschner, T., Benz, P., Tucha, O., Preier, M., Lange, K. W., Reiners, K., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.6.999 · Cited by 377
Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases
Gagnon, J.-F., Postuma, R. B., Mazza, S., Doyon, J., & Montplaisir, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70441-0 · Cited by 374
Kang, J.-H. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3861 · Cited by 367
Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease
Dickson, D. W., Fujishiro, H., DelleDonne, A., Menke, J., Ahmed, Z., Klos, K. J., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0345-7 · Cited by 364
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
Vingerhoets, F. J. G., Schulzer, M., Calne, D. B., & Snow, B. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410111 · Cited by 359
Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
Bezard, E., Gross, C. E., & Brotchie, J. M. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00038-9 · Cited by 350
Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A., & Montplaisir, J. Y. (2012) · Brain · doi:10.1093/brain/aws093 · Cited by 348
[ 123 I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., Oakes, D., & Seibyl, J. (2001) · Neurology · doi:10.1212/wnl.57.11.2089 · Cited by 347
Hilton, D., Stephens, M., Kirk, L., Edwards, P., Potter, R., Zajicek, J., Broughton, E., Hagan, H., & Carroll, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1214-6 · Cited by 345
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343
Schwarz, S. T., Afzal, M., Morgan, P. S., Bajaj, N., Gowland, P. A., & Auer, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093814 · Cited by 330
A systematic review of depression and mental illness preceding Parkinson's disease
Ishihara, L., & Brayne, C. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00579.x · Cited by 313
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound
Berg, D., Becker, G., Zeiler, B., Tucha, O., Hofmann, E., Preier, M., Benz, P., Jost, W., Reiners, K., & Lange, K. W. (1999) · Neurology · doi:10.1212/wnl.53.5.1026 · Cited by 312
Iranzo, A., Valldeoriola, F., Lomeña, F., Molinuevo, J. L., Serradell, M., Salamero, M., Cot, A., Ros, D., Pavía, J., Santamaria, J., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70152-1 · Cited by 311
Hilker, R., Schweitzer, K., Coburger, S., Ghaemi, M., Weisenbach, S., Jacobs, A. H., Rudolf, J., Herholz, K., & Heiss, W.-D. (2005) · Archives of Neurology · doi:10.1001/archneur.62.3.378 · Cited by 293
Postuma, R. B., Iranzo, A., Hogl, B., Arnulf, I., Ferini‐Strambi, L., Manni, R., Miyamoto, T., Oertel, W., Dauvilliers, Y., Ju, Y., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24385 · Cited by 291
Skin nerve α-synuclein deposits: A biomarker for idiopathic Parkinson disease
Donadio, V., Incensi, A., Leta, V., Giannoccaro, M. P., Scaglione, C., Martinelli, P., Capellari, S., Avoni, P., Baruzzi, A., & Liguori, R. (2014) · Neurology · doi:10.1212/wnl.0000000000000316 · Cited by 290
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2
Pankratz, N., Beecham, G. W., DeStefano, A. L., Dawson, T. M., Doheny, K. F., Factor, S. A., Hamza, T. H., Hung, A. Y., Hyman, B. T., Ivinson, A. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22687 · Cited by 285
Phosphorylated α-Synuclein in Parkinson’s Disease
Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M.-Y., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 275
Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7 T MRI
Blazejewska, A. I., Schwarz, S. T., Pitiot, A., Stephenson, M. C., Lowe, J., Bajaj, N., Bowtell, R. W., Auer, D. P., & Gowland, P. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829e6fd2 · Cited by 269
Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., & Berg, D. (2015) · Movement Disorders · doi:10.1002/mds.26071 · Cited by 267
Neuropathology of non-motor features of Parkinson disease
Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Klos, K. J., & Ahlskog, J. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70769-2 · Cited by 266
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
Ross, G. W., Petrovitch, H., Abbott, R. D., Nelson, J., Markesbery, W., Davis, D., Hardman, J., Launer, L., Masaki, K., Tanner, C. M., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20226 · Cited by 260
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
Propagation of prions causing synucleinopathies in cultured cells
Woerman, A. L., Stöhr, J., Aoyagi, A., Rampersaud, R., Krejciova, Z., Watts, J. C., Ohyama, T., Patel, S., Widjaja, K., Oehler, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513426112 · Cited by 247
Postuma, R. B., Gagnon, J., Vendette, M., Desjardins, C., & Montplaisir, J. Y. (2011) · Annals of Neurology · doi:10.1002/ana.22282 · Cited by 241
Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology
Doppler, K., Ebert, S., Üçeyler, N., Trenkwalder, C., Ebentheuer, J., Volkmann, J., & Sommer, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1284-0 · Cited by 238
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., & Brice, A. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f476 · Cited by 238
Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders
The Arizona Parkinson’s Disease Consortium, Beach, T. G., White, C. L., Hladik, C. L., Sabbagh, M. N., Connor, D. J., Shill, H. A., Sue, L. I., Sasse, J., Bachalakuri, J., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0450-7 · Cited by 235
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease
Devic, I., Hwang, H., Edgar, J. S., Izutsu, K., Presland, R., Pan, C., Goodlett, D. R., Wang, Y., Armaly, J., Tumas, V., et al. (2011) · Brain · doi:10.1093/brain/awr015 · Cited by 222
Scherfler, C., Frauscher, B., Schocke, M., Iranzo, A., Gschliesser, V., Seppi, K., Santamaria, J., Tolosa, E., Högl, B., Poewe, W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22245 · Cited by 220
Self-citationSignificance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease
Shi, M., Zabetian, C. P., Hancock, A. M., Ginghina, C., Hong, Z., Yearout, D., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.009 · Cited by 219
α-Synuclein in cutaneous autonomic nerves
Wang, N., Gibbons, C. H., Lafo, J., & Freeman, R. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a9f449 · Cited by 217
Nigral pathology and parkinsonian signs in elders without Parkinson disease
Buchman, A. S., Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C., Schneider, J. A., & Bennett, D. A. (2012) · Annals of Neurology · doi:10.1002/ana.22588 · Cited by 213
Cerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
Total cholesterol and the risk of Parkinson disease
Hu, G., Antikainen, R., Jousilahti, P., Kivipelto, M., & Tuomilehto, J. (2008) · Neurology · doi:10.1212/01.wnl.0000312511.62699.a8 · Cited by 206
Evolution of Prodromal Clinical Markers of Parkinson Disease in a GBA Mutation–Positive Cohort
Beavan, M., McNeill, A., Proukakis, C., Hughes, D. A., Mehta, A., & Schapira, A. H. V. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2950 · Cited by 205
Nalls, M. A., McLean, C. Y., Rick, J., Eberly, S., Hutten, S. J., Gwinn, K., Sutherland, M., Martinez, M., Heutink, P., Williams, N. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00178-7 · Cited by 204
Gao, L., Tang, H., Nie, K., Wang, L., Zhao, J., Gan, R., Huang, J., Zhu, R., Feng, S., Duan, Z., et al. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.961454 · Cited by 203
Bowel movement frequency in late‐life and incidental Lewy bodies
Abbott, R. D., Ross, G. W., Petrovitch, H., Tanner, C. M., Davis, D. G., Masaki, K. H., Launer, L. J., Curb, J. D., & White, L. R. (2007) · Movement Disorders · doi:10.1002/mds.21560 · Cited by 203
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
Mencacci, N. E., Isaias, I. U., Reich, M. M., Ganos, C., Plagnol, V., Polke, J. M., Bras, J., Hersheson, J., Stamelou, M., Pittman, A. M., et al. (2014) · Brain · doi:10.1093/brain/awu179 · Cited by 201
The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease
Gaenslen, A., Swid, I., Liepelt‐Scarfone, I., Godau, J., & Berg, D. (2011) · Movement Disorders · doi:10.1002/mds.23499 · Cited by 198
Toward a redefinition of Parkinson's disease
Stern, M. B., Lang, A., & Poewe, W. (2012) · Movement Disorders · doi:10.1002/mds.24051 · Cited by 195
Self-citationPlasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease
Khoo, S. K., Petillo, D., Kang, U. J., Resau, J. H., Berryhill, B., Linder, J., Forsgren, L., Neuman, L. A., & Tan, A. C. (2012) · Journal of Parkinson's Disease · doi:10.3233/jpd-012144 · Cited by 194
Association of olfactory dysfunction with incidental Lewy bodies
Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M., Davis, D. G., Nelson, J., Markesbery, W. R., Hardman, J., Masaki, K., Launer, L., et al. (2006) · Movement Disorders · doi:10.1002/mds.21076 · Cited by 194
Unger, M. M., Belke, M., Menzler, K., Heverhagen, J. T., Keil, B., Stiasny-Kolster, K., Rosenow, F., Diederich, N. J., Mayer, G., Möller, J. C., et al. (2010) · Sleep · doi:10.1093/sleep/33.6.767 · Cited by 190
Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD
Mahlknecht, P., Iranzo, A., Högl, B., Frauscher, B., Müller, C., Santamaría, J., Tolosa, E., Serradell, M., Mitterling, T., Gschliesser, V., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001265 · Cited by 186
Self-citationLewy pathology and neurodegeneration in premotor Parkinson's disease
Del Tredici, K., & Braak, H. (2012) · Movement Disorders · doi:10.1002/mds.24921 · Cited by 185
Premotor Parkinson’s disease: Concepts and definitions
Siderowf, A., & Lang, A. E. (2012) · Movement Disorders · doi:10.1002/mds.24954 · Cited by 174
Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study
Jennings, D., Siderowf, A., Stern, M., Seibyl, J., Eberly, S., Oakes, D., Marek, K., & For the PARS Investigators (2014) · Neurology · doi:10.1212/wnl.0000000000000960 · Cited by 171
Gait alterations in healthy carriers of the LRRK2 G2019S mutation
Mirelman, A., Gurevich, T., Giladi, N., Bar‐Shira, A., Orr‐Urtreger, A., & Hausdorff, J. M. (2011) · Annals of Neurology · doi:10.1002/ana.22165 · Cited by 166
Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease
Ritz, B., Lee, P.-C., Lassen, C. F., & Arah, O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000879 · Cited by 160
Biopsies of olfactory epithelium in patients with Parkinson's disease
Witt, M., Bormann, K., Gudziol, V., Pehlke, K., Barth, K., Minovi, A., Haehner, A., Reichmann, H., & Hummel, T. R. (2009) · Movement Disorders · doi:10.1002/mds.22464 · Cited by 160
Reiter, E., Mueller, C., Pinter, B., Krismer, F., Scherfler, C., Esterhammer, R., Kremser, C., Schocke, M. F. H., Wenning, G. K., Poewe, W. H., et al. (2015) · Movement Disorders · doi:10.1002/mds.26171 · Cited by 157
Self-citationColonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease
Visanji, N. P., Marras, C., Kern, D. S., AlDakheel, A., Gao, A. F., Liu, L. W. C., Lang, A. E., & Hazrati, L. (2015) · Neurology · doi:10.1212/wnl.0000000000001240 · Cited by 156
Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder
Sprenger, F., Stefanova, N., Gelpí, E., Seppi, K., Navarro‐Otano, J., Offner, F. A., Vilas, D., Valldeoriola, F., Pont‐Sunyer, C., Aldecoa, I., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002126 · Cited by 155
Self-citationMild Parkinsonian signs: An overview of an emerging concept
Louis, E., & Bennett, D. A. (2007) · Movement Disorders · doi:10.1002/mds.21433 · Cited by 154
Berg, D., Seppi, K., Behnke, S., Liepelt, I., Schweitzer, K., Stockner, H., Wollenweber, F., Gaenslen, A., Mahlknecht, P., Spiegel, J., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.141 · Cited by 151
Self-citationStatins, plasma cholesterol, and risk of Parkinson's disease: A prospective study
Huang, X., Alonso, Á., Guo, X., Umbach, D. M., Lichtenstein, M. L., Ballantyne, C. M., Mailman, R. B., Mosley, T. H., & Chen, H. (2015) · Movement Disorders · doi:10.1002/mds.26152 · Cited by 145
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel‐Döring, F., Ebentheuer, J., Trenkwalder, C., & Schlossmacher, M. G. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.004 · Cited by 144
Plasma apolipoprotein A1 as a biomarker for Parkinson disease
Qiang, J. K., Wong, Y. C., Siderowf, A. D., Hurtig, H. I., Xie, S. X., Lee, V. M. ‐., Trojanowski, J. Q., Yearout, D., Leverenz, J. B., Montine, T. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23872 · Cited by 143
Polygenic risk of P arkinson disease is correlated with disease age at onset
Escott‐Price, V., Nalls, M. A., Morris, H. R., Lubbe, S. J., Brice, A., Gasser, T., Heutink, P., Wood, N. W., Hardy, J., Singleton, A., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24335 · Cited by 143
Expression pattern and localization of alpha-synuclein in the human enteric nervous system
Böttner, M., Zorenkov, D., Hellwig, I., Barrenschee, M., Harde, J., Fricke, T., Deuschl, G., Egberts, J., Becker, T., Fritscher‐Ravens, A., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.07.018 · Cited by 143
Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease
Rolheiser, T. M., Fulton, H. G., Good, K. P., Fisk, J. D., McKelvey, J. R., Scherfler, C., Khan, N. M., Leslie, R. A., & Robertson, H. A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-5915-2 · Cited by 143
Scherfler, C., Schocke, M. F. H., Seppi, K., Esterhammer, R., Brenneis, C., Jaschke, W. R., Wenning, G. K., & Poewe, W. H. (2005) · Brain · doi:10.1093/brain/awh674 · Cited by 140
Self-citationSubmandibular gland needle biopsy for the diagnosis of Parkinson disease
Adler, C. H., Dugger, B. N., Hinni, M. L., Lott, D. G., Driver‐Dunckley, E. D., Hidalgo, J., Henry-Watson, J., Serrano, G. E., Sue, L. I., Nagel, T. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000204 · Cited by 140
A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease
Pouclet, H., Lebouvier, T., Coron, E., Bruley des Varannes, S., Rouaud, T., Roy, M., Neunlist, M., & Derkinderen, P. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.014 · Cited by 138
Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts
Kraemmer, J., Kovacs, G. G., Perju-Dumbrava, L., Pirker, S., Traub-Weidinger, T., & Pirker, W. (2014) · Movement Disorders · doi:10.1002/mds.25975 · Cited by 132
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease
Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., Liepelt‐Scarfone, I., Pausch, C., Schneider, N. R. E., Gaenslen, A., et al. (2012) · Movement Disorders · doi:10.1002/mds.25192 · Cited by 130
Self-citationOverexpression of blood microRNAs 103a, 30b, and 29a in l -dopa–treated patients with PD
Serafin, A., Foco, L., Zanigni, S., Blankenburg, H., Picard, A., Zanon, A., Giannini, G., Pichler, I., Facheris, M., Cortelli, P., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001258 · Cited by 125
Huang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B., & Ross, G. W. (2008) · Movement Disorders · doi:10.1002/mds.22013 · Cited by 124
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
The PRIPS study: screening battery for subjects at risk for P arkinson's disease
Berg, D., Godau, J., Seppi, K., Behnke, S., Liepelt‐Scarfone, I., Lerche, S., Stockner, H., Gaenslen, A., Mahlknecht, P., Huber, H., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03798.x · Cited by 123
Self-citationDiscontinuation of statin therapy associates with Parkinson disease: A population-based study
Lee, Y., Lin, C., Wu, R., Lin, M.-S., Lin, J., Chang, C., & Lai, M. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d873c · Cited by 122
PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results
Noyce, A. J., Bestwick, J., Silveira‐Moriyama, L., Hawkes, C. H., Knowles, C. H., Hardy, J., Giovannoni, G., Nageshwaran, S., Osborne, C., Lees, A. J., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305420 · Cited by 115
Erro, R., Picillo, M., Vitale, C., Amboni, M., Moccia, M., Longo, K., Cozzolino, A., Giordano, F., Rosa, A. D., Michele, G. D., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303419 · Cited by 115
Ibarretxe‐Bilbao, N., Junqué, C., Martí, M. J., Valldeoriola, F., Vendrell, P., Bargalló, N., Zarei, M., & TOLOSA, E. S. (2010) · Movement Disorders · doi:10.1002/mds.23208 · Cited by 112
Ponsen, M. M., Stoffers, D., Wolters, E. C., Booij, J., & Berendse, H. W. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.183715 · Cited by 112
A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson’s disease
Pouclet, H., Lebouvier, T., Coron, E., Varannes, S. B. D., Neunlist, M., & Derkinderen, P. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01887.x · Cited by 111
Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature
Schneider, S. A., Böttner, M., Alexoudi, A., Zorenkov, D., Deuschl, G., & Wedel, T. (2015) · European Journal of Neurology · doi:10.1111/ene.12753 · Cited by 109
Probable RBD and association with neurodegenerative disease markers: A population‐based study
Mahlknecht, P., Seppi, K., Frauscher, B., Kiechl, S. J., Willeit, J., Stockner, H., Djamshidian, A., Nocker, M., Rastner, V., Defrancesco, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26350 · Cited by 104
Self-citationMotor signs in the prodromal phase of Parkinson's disease
Maetzler, W., & Hausdorff, J. M. (2012) · Movement Disorders · doi:10.1002/mds.24973 · Cited by 104
Changing Concepts of Alzheimer Disease
McKhann, G. M. (2011) · JAMA · doi:10.1001/jama.2011.810 · Cited by 95
Frentz, D., Boucher, C. A., Assel, M., Luca, A. D., Fabbiani, M., Incardona, F., Libin, P., Manca, N., Müller, V., Nualláin, B. Ó., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011505 · Cited by 95
Swanson, C. R., Berlyand, Y., Xie, S. X., Alcalay, R. N., Chahine, L. M., & Chen‐Plotkin, A. S. (2015) · Movement Disorders · doi:10.1002/mds.26290 · Cited by 94
Impaired Trunk Stability in Individuals at High Risk for Parkinson's Disease
Maetzler, W., Mancini, M., Liepelt‐Scarfone, I., Müller, K., Becker, C., van Lummel, R. C., Ainsworth, E., Hobert, M. A., Streffer, J. R., Berg, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032240 · Cited by 92
van Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., & van de Berg, W. D. J. (2014) · European Journal of Neurology · doi:10.1111/ene.12176 · Cited by 88
Five‐year follow‐up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder
Iranzo, Á., Stockner, H., Serradell, M., Seppi, K., Valldeoriola, F., Frauscher, B., Molinuevo, J. L., Vilaseca, I., Mitterling, T., Gaig, C., et al. (2014) · Movement Disorders · doi:10.1002/mds.26055 · Cited by 86
Self-citationLinking Smoking, Coffee, Urate, and Parkinson’s Disease – A Role for Gut Microbiota?
Scheperjans, F., Pekkonen, E., Kaakkola, S., & Auvinen, P. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150557 · Cited by 83
Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease
Sierra, M., Sánchez‐Juan, P., Martínez-Rodríguez, M. I., Aramburu, I. G., García‐Gorostiaga, I., Quirce, M. R., Palacio, E., CARRIL, J. M., Berciano, J., Combarros, O., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31828250d6 · Cited by 83
Microglia activation is related to substantia nigra echogenicity
Berg, D., Godau, J., Riederer, P. F., Gerlach, M., & Arzberger, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0504-6 · Cited by 83
α-synuclein Imaging: A Critical Need for Parkinson's Disease Research
Eberling, J. L., Dave, K. D., & Frasier, M. A. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130247 · Cited by 81
Phosphorylated alpha-Synuclein in Parkinson's Disease
Wang, Y., Shi, M., Chung, K. A., et al. (2012) · Science Translational Medicine · Cited by 76
Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach
van Nuenen, B. F. L., van Eimeren, T., van der Vegt, J. P. M., Buhmann, C., Klein, C., Bloem, B. R., & Siebner, H. R. (2009) · Movement Disorders · doi:10.1002/mds.22635 · Cited by 71
Behnke, S., Schroeder, U., Dillmann, U., Buchholz, H., Schreckenberger, M., Fuss, G., Reith, W., Berg, D., & Krick, C. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.05.072 · Cited by 57
Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology
Folgoas, E., Lebouvier, T., Leclair‐Visonneau, L., Cersosimo, M. G., Barthelaix, A., Derkinderen, P., & Letournel, F. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.07.016 · Cited by 47
Biochemical premotor biomarkers for Parkinson's disease
Mollenhauer, B., & Zhang, J. (2012) · Movement Disorders · doi:10.1002/mds.24956 · Cited by 45
Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study
Mahlknecht, P., Seppi, K., Stockner, H., Nocker, M., Scherfler, C., Kiechl, S. J., Willeit, J., Schmidauer, C., Gasperi, A., Rungger, G., et al. (2013) · Neurodegenerative Diseases · doi:10.1159/000348595 · Cited by 33
Self-citationNeuroimaging: Current role in detecting pre‐motor Parkinson's disease
Godau, J., Hussl, A., Lolekha, P., Stoessl, A. J., & Seppi, K. (2012) · Movement Disorders · doi:10.1002/mds.24976 · Cited by 31
Self-citationQuitting smoking: An early non-motor feature of Parkinson's disease?
Moccia, M., Erro, R., Picillo, M., Vassallo, E., Vitale, C., Longo, K., Amboni, M., Santangelo, G., Palladino, R., Nardone, A., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.008 · Cited by 23
Cerebrospinal fluid α‐synuclein levels in Parkinson's disease – changed or unchanged?
Zetterberg, H., Petzold, M., & Magdalinou, N. K. (2013) · European Journal of Neurology · doi:10.1111/ene.12326 · Cited by 17
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationChallenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Self-citationIdiopathic REM sleep behaviour disorder and neurodegeneration — an update
Högl, B., Stefani, A., & Videnovic, A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.157 · Cited by 540
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Rey, N. L., Steiner, J. A., Maroof, N., Luk, K. C., Madaj, Z., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160368 · Cited by 388
Metadata
- Authors
- Mahlknecht, P., Seppi, K., & Poewe, W.
- Venue
- Journal of Parkinson's Disease
- Publisher
- SAGE Publications
- Published
- 2015-10-17
- Volume
- 5
- Issue
- 4
- Pages
- 681-697
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- OpenAlex
- W2179197468
- Cited by
- 288
- References
- 149
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.